An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
PROMISE
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects Who Relapsed After Previous Interferon-based Therapy
3 other identifiers
interventional
394
12 countries
63
Brief Summary
The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in patients who are infected with genotype 1 hepatitis C virus who relapsed after previous interferon-based therapy. Patients will also receive peginterferon alfa-2a and ribavirin as part of their treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Feb 2011
63 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 7, 2011
CompletedFirst Posted
Study publicly available on registry
January 24, 2011
CompletedStudy Start
First participant enrolled
February 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2013
CompletedResults Posted
Study results publicly available
April 23, 2014
CompletedApril 23, 2014
March 1, 2014
2 years
January 7, 2011
February 3, 2014
March 26, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
The table below shows the percentage of participants in each treatment group who achieved a SVR12, defined as the percentage of participants with undetectable plasma Hepatitis C virus ribonucleic acid 12 weeks after planned end of treatment.
Week 36 or Week 60
Secondary Outcomes (29)
The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)
Week 72
The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)
Week 48 or Week 72
The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)
Week 28 or Week 52
Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
Day 3, Week 1, Week 4, Week 12, Week 24, and Week 48
Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
Day 3, Week 1, Week 4, Week 12, Week 24, and Week 48
- +24 more secondary outcomes
Study Arms (2)
TMC435
EXPERIMENTALTMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
Placebo
PLACEBO COMPARATORPlacebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
Interventions
150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Eligibility Criteria
You may qualify if:
- Genotype 1 hepatitis C infection (confirmed at screening)
- Have previously received peginterferon-based therapy for at least 24 weeks with documented HCV RNA at last measurement and relapsed within 1 year of last taking medication
- Liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection
- Must agree to use 2 forms of effective contraception throughout study (both males and females)
You may not qualify if:
- Infection with HIV or non-genotype 1 hepatitis C
- Liver disease not related to hepatitic C infection
- Hepatic decompensation
- Significant laboratory abnormalities or other active diseases
- Pregnant or planning to become pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (68)
Unknown Facility
Bakersfield, California, United States
Unknown Facility
Aurora, Colorado, United States
Unknown Facility
Jacksonville, Florida, United States
Unknown Facility
Orlando, Florida, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Crestview Hills, Kentucky, United States
Unknown Facility
Saint Paul, Minnesota, United States
Unknown Facility
Jackson, Mississippi, United States
Unknown Facility
Germantown, Tennessee, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Adelaide, Australia
Unknown Facility
Kingswood, Australia
Unknown Facility
Melbourne, Australia
Unknown Facility
Sydney, Australia
Unknown Facility
Woolloongabba, Australia
Unknown Facility
Vienna, Austria
Unknown Facility
Antwerp, Belgium
Unknown Facility
Bruges, Belgium
Unknown Facility
Brussels, Belgium
Unknown Facility
Ghent, Belgium
Unknown Facility
Leuven, Belgium
Unknown Facility
Vancouver, British Columbia, Canada
Unknown Facility
Ottawa, Ontario, Canada
Unknown Facility
Toronto, Ontario, Canada
Unknown Facility
Montreal, Quebec, Canada
Unknown Facility
Créteil, France
Unknown Facility
Grenoble, France
Unknown Facility
Lyon, France
Unknown Facility
Nice, France
Unknown Facility
Paris, France
Unknown Facility
Rennes, France
Unknown Facility
Vandœuvre-lès-Nancy, France
Unknown Facility
Berlin, Germany
Unknown Facility
Düsseldorf, Germany
Unknown Facility
Frankfurt, Germany
Unknown Facility
Freiburg im Breisgau, Germany
Unknown Facility
Halle, Germany
Unknown Facility
Hamburg, Germany
Unknown Facility
Kiel, Germany
Unknown Facility
Leipzig, Germany
Unknown Facility
München, Germany
Unknown Facility
Würzburg, Germany
Unknown Facility
Auckland, New Zealand
Unknown Facility
Christchurch, New Zealand
Unknown Facility
Hamilton, New Zealand
Unknown Facility
Bialystok, Poland
Unknown Facility
Bydgoszcz, Poland
Unknown Facility
Czeladź, Poland
Unknown Facility
Kielce, Poland
Unknown Facility
Krakow, Poland
Unknown Facility
Warsaw, Poland
Unknown Facility
Ponce Pr, Puerto Rico
Unknown Facility
San Juan, Puerto Rico
Unknown Facility
Moscow, Russia
Unknown Facility
Saint Petersburg, Russia
Unknown Facility
Samara, Russia
Unknown Facility
Smolensk, Russia
Unknown Facility
Stavropol, Russia
Unknown Facility
Barcelona, Spain
Unknown Facility
Madrid, Spain
Unknown Facility
Seville, Spain
Unknown Facility
Valencia, Spain
Unknown Facility
Birmingham, United Kingdom
Unknown Facility
Derby, United Kingdom
Unknown Facility
Glasgow, United Kingdom
Unknown Facility
London, United Kingdom
Unknown Facility
Plymouth, United Kingdom
Related Publications (2)
Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, Buelens A, Ceulemans H, Beumont M, Picchio G, De Meyer S. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015 May;62(5):1008-14. doi: 10.1016/j.jhep.2014.11.032. Epub 2014 Nov 28.
PMID: 25445400DERIVEDForns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014 Jun;146(7):1669-79.e3. doi: 10.1053/j.gastro.2014.02.051. Epub 2014 Mar 3.
PMID: 24602923DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Global Clinical Development Manager
- Organization
- Jan-Cil France
Study Officials
- STUDY DIRECTOR
Janssen R&D Ireland Clinical Trial
Janssen R&D Ireland
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 7, 2011
First Posted
January 24, 2011
Study Start
February 1, 2011
Primary Completion
February 1, 2013
Study Completion
February 1, 2013
Last Updated
April 23, 2014
Results First Posted
April 23, 2014
Record last verified: 2014-03